LIDDS Stock Overview
A drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
LIDDS AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.11 |
| 52 Week High | SEK 0.23 |
| 52 Week Low | SEK 0.082 |
| Beta | 0.34 |
| 1 Month Change | -46.74% |
| 3 Month Change | 10.10% |
| 1 Year Change | -19.08% |
| 3 Year Change | -98.17% |
| 5 Year Change | -99.09% |
| Change since IPO | -98.96% |
Recent News & Updates
Recent updates
Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation
May 26
Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation
Dec 15Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?
Jul 19Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation
Mar 08We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate
Nov 23
Shareholder Returns
| LIDDS | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | -7.7% | -3.0% |
| 1Y | -19.1% | -4.1% | 3.4% |
Return vs Industry: LIDDS underperformed the Swedish Biotechs industry which returned -4.1% over the past year.
Return vs Market: LIDDS underperformed the Swedish Market which returned 3.4% over the past year.
Price Volatility
| LIDDS volatility | |
|---|---|
| LIDDS Average Weekly Movement | 24.5% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: LIDDS's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: LIDDS's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1 | Mats Wiking | www.liddspharma.com |
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments.
LIDDS AB (publ) Fundamentals Summary
| LIDDS fundamental statistics | |
|---|---|
| Market cap | SEK 15.63m |
| Earnings (TTM) | -SEK 4.31m |
| Revenue (TTM) | SEK 32.00k |
488.3x
P/S Ratio-3.6x
P/E RatioIs LIDDS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIDDS income statement (TTM) | |
|---|---|
| Revenue | SEK 32.00k |
| Cost of Revenue | SEK 3.44m |
| Gross Profit | -SEK 3.40m |
| Other Expenses | SEK 906.00k |
| Earnings | -SEK 4.31m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 06, 2025
| Earnings per share (EPS) | -0.032 |
| Gross Margin | -10,640.63% |
| Net Profit Margin | -13,471.88% |
| Debt/Equity Ratio | 0% |
How did LIDDS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 02:09 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LIDDS AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ethel Szpilman Luvall | Redeye |